Abstract
We report a case of hepatocellular carcinoma (HCC) arising in nonalcoholic steatohepatitis (NASH). The patient, a 64-year-old man, was incidentally found to have multiple tumors in the liver when admitted for pneumonia. He had been obese, had been receiving a standard dose of valproic acid since clipping surgery for subarachnoid hemorrhage 17 years previously, and had not consumed any alcohol since the surgery. Laboratory data revealed moderate hyperlipidemia and no evidence of diabetes mellitus, hepatitis B or C infection. The patient died of hepatic insufficiency, and an autopsy was performed. A tumor, a maximum of 13 cm in diameter, grossly occupied the entire left lobe and one third of the right lobe of the liver. Histologically, moderately differentiated HCC was found with foci of poorly differentiated HCC. The non-tumorous area showed NASH with moderate bridging fibrosis, without interface hepatitis, hemochromatosis, or copper accumulation. In this patient, obesity, hyperlipidemia, and long-term treatment with valproic acid could have all been associated with induction of NASH. The present case suggests that HCC could develop in non-cirrhotic NASH liver, and that chronic inflammation in itself could be an important risk factor in the development of HCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231
Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS (2001) Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56:172–177
Brunt EM (2004) Nonalcoholic steatohepatitis. Semin Liver Dis 24:3–20
Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140
Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM (2004) Obesity and hepatocellular carcinoma. Gastroenterology 127:S97–S103
Cotrim HP, Parana R, Braga E, Lyra L (2000) Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 95:3018–3019
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17–26
Farrell GC (2002) Drugs and steatohepatitis. Semin Liver Dis 22:185–194
Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978
Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21:361–370
Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349–1354
Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, Kurokawa F, Maeyama S, Okita K (2004) Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 39:391–396
Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:1202–1219 (Erratum in: Hepatology 2003;38:536)
Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N (2001) Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7:797–801
Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K (2001) Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol 33:195–200
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80
Schafer DF, Sorrell MF (1999) Hepatocellular carcinoma. Lancet 353:1253–1257
Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154–160
Singh G, Driever PH, Sander JW (2005) Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 128:7–17
Soga M, Kishimoto Y, Kawamura Y, Inagaki S, Makino S, Saibara T (2003) Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver. Cancer Lett 196:43–48
Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY (2005) Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A 102:4120–4125
Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y (2001) Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51:127–131
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sato, K., Ueda, Y., Ueno, K. et al. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 447, 996–999 (2005). https://doi.org/10.1007/s00428-005-0042-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-005-0042-z